Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Critical Mineral Executive Order Issued by President Donald Trump (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Savara Inc SVRA

Healthcare Biotechnology
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled... see more

Current News (NDAQ:SVRA)

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Business Wire 8 days ago

Savara Announces U.S. Launch of the aPAP ClearPath(TM) Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Business Wire March 6, 2025

Savara Announces Participation in the Leerink Global Healthcare Conference

Business Wire March 3, 2025

Savara Announces New Employment Inducement Grant

Business Wire February 14, 2025

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Business Wire January 30, 2025

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Business Wire January 29, 2025

Savara Announces New Employment Inducement Grant

Business Wire December 23, 2024

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Business Wire December 18, 2024

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire December 17, 2024
View More News ››

Opinion & Analysis (NDAQ:SVRA)

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Streetwise Reports January 2, 2020
View More Opinion ››

Bullboard Posts (NDAQ:SVRA)

Savara Announces Participation in Upcoming Healthcare Confer

JUST IN: $SVRA Savara Announces Participation in Upcoming Healthcare ConferencesSavara Inc. (Nasdaq: SVRA ) (the Company), a clinical...
whytestocks - November 13, 2024

Savara to Host Analyst and Investor Webinar on September 30,

News; $SVRA Savara to Host Analyst and Investor Webinar on September 30, 2024Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage...
whytestocks - September 23, 2024

Savara Announces Pricing of $100.0 Million Underwritten Offe

BREAKING NEWS: $SVRA Savara Announces Pricing of $100.0 Million Underwritten Offering of Common StockSavara Inc. (Nasdaq: SVRA), a...
whytestocks - June 28, 2024

it's a buy today for me

at $3.37 per share,it looks like a this one will make a comeback and it was on my watchlist,so glta.
coolfooldumbguy - December 30, 2019

the bottom is past for

this one, I was really out of it today,so glta as I will try to stay sober for the rest of the week.
coolfooldumbguy - June 19, 2019

watching this one for

an entry point,so glta.
coolfooldumbguy - June 18, 2019
View more Bullboard ››

Visionstate Corp.

Visionstate Corp.

Visionstate Corp.is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »